Erasca Inc

Schall, Brown & Schwartz LLP reminds Erasca, Inc. investors of a pending securities fraud class action, with a lead plaintiff deadline of August 10, 2026. The lawsuit covers shareholders who purchased ERAS shares between January 14, 2025 and April 26, 2026, alleging the company made false and misleading statements about its preclinical data for ERAS-0015. The complaint claims Erasca's data relied on an improper comparison to Revolution Medicines, Inc., exposing it to patent violation risks and lacking a basis for its optimistic projections. When the market learned the truth, investors suffered damages.

Bragar Eagel & Squire reminds Erasca investors that the deadline to seek lead plaintiff appointment in a securities class action is August 10, 2026. The lawsuit, filed in the Southern District of California, covers purchasers of Erasca common stock between January 14, 2025 and April 26, 2026. It alleges that the company made false statements and failed to disclose that ERAS-0015 preclinical data relied on improper comparisons to Revolution Medicines, exposing Erasca to patent and trade secret violation risks. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing its share price to drop 48 percent from $19.15 to $9.90. Investors with losses can contact the firm at investigations@bespc.com or (212) 355-4648.

Hagens Berman is investigating claims in a securities class action against Erasca, Inc. alleging the company misled investors about its lead oncology candidate ERAS-0015. The investigation follows disclosures on April 27 and 28, 2026, that triggered a sharp stock decline and wiped out over $2.8 billion in market capitalization. The litigation claims Erasca used flawed preclinical comparisons to assert superiority over competing therapies, concealed intellectual property disputes with Revolution Medicines, and downplayed safety risks that later surfaced after a patient death in the ERAS-0015 trial. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek appointment as lead plaintiff.

The Law Offices of Howard G. Smith has issued a deadline alert for investors seeking to lead securities fraud class actions against First Solar, Embecta, Black Rock Coffee Bar, and Erasca. The lead plaintiff deadline for Erasca is August 10, 2026, while deadlines for Embecta and Black Rock Coffee Bar fall on August 17, 2026, and the deadline for First Solar is August 24, 2026. The complaints allege that each company made materially false or misleading statements or failed to disclose adverse facts about their business, operations, and prospects during the respective class periods. Investors who suffered losses are encouraged to contact the law firm to discuss their legal rights.

Bernstein Liebhard LLP reminds Erasca, Inc. investors of an August 10, 2026 deadline to join a securities fraud class action lawsuit. The lawsuit, filed on behalf of investors who purchased or acquired Erasca common stock between January 14, 2025 and April 26, 2026, alleges that the company and certain senior officers made materially false and misleading statements about its business operations, growth prospects, and financial stability, causing the stock to trade at artificially inflated prices. When the truth was disclosed, investors allegedly suffered significant losses. Investors who wish to serve as lead plaintiff must file papers by the deadline, though participation in any recovery does not require serving as lead plaintiff. Bernstein Liebhard LLP, which has recovered over $3.5 billion for clients since 1993, is handling the case on a contingency fee basis.

Rosen Law Firm reminds purchasers of Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Erasca, along with its CEO and CFO, made false and misleading statements about its lead oncology drug candidate, ERAS-0015, touting it as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. Investors who purchased Erasca common stock during the class period may be entitled to compensation without payment of out-of-pocket fees through a contingency fee arrangement. To join the class action or seek lead plaintiff status, investors must move the Court no later than August 10, 2026.

Rosen Law Firm reminds purchasers of Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Erasca, along with its CEO and CFO, made false and misleading statements about its lead oncology drug candidate ERAS-0015, touting it as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' competing drug candidate RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. Investors with losses in excess of $100,000 are encouraged to secure counsel. To join the Erasca class action, go to https://rosenlegal.com/cases/erasca-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026.

Hagens Berman is investigating claims in a securities class action against Erasca, Inc., alleging the company misled investors about its lead oncology candidate ERAS-0015. The litigation claims Erasca used flawed preclinical comparisons to tout superiority over Revolution Medicines' RMC-6236, concealed intellectual property disputes that exposed it to patent infringement and trade secret misappropriation claims, and downplayed safety risks that later included a patient death. On April 27–28, 2026, disclosures of a legal challenge from Revolution Medicines and adverse clinical data triggered a sharp stock decline that wiped out over $2.8 billion in market capitalization. The class period runs from January 14, 2025, to April 26, 2026, and the lead plaintiff deadline is August 10, 2026.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Erasca, Inc. in the United States District Court for the Southern District of California. The lawsuit covers purchasers of Erasca common stock between January 14, 2025 and April 26, 2026, with a lead plaintiff deadline of August 10, 2026. The complaint alleges that defendants made false and misleading statements regarding ERAS-0015, including that its preclinical data relied on improper comparisons to Revolution Medicines and risked patent and trade secret violations. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing the stock to drop $9.25 per share, or approximately 48%, from $19.15 to $9.90. Investors who suffered losses can contact the firm at investigations@bespc.com or (212) 355-4648.

Glancy Prongay Wolke & Rotter LLP reminds Erasca, Inc. shareholders of the August 10, 2026 deadline to seek lead plaintiff status in a class action covering purchases of Erasca common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges the company made misleading statements and failed to disclose that its drug candidate ERAS-0015 involved improper preclinical data comparisons to Revolution Medicines and risked patent and trade secret violations. On April 27, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing the stock to drop 10.9% to $19.15 per share. After market hours that day, Erasca reported a patient death in a Phase 1 trial of ERAS-0015, sending shares down an additional 48.3% to $9.90 on April 28, 2026.

The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Erasca, Nano-X Imaging, Microsoft, and Black Rock Coffee Bar, with lead plaintiff deadlines approaching in August 2026. For Erasca, the class period runs from January 14, 2025 to April 26, 2026, with a deadline of August 10, 2026, and the complaint alleges that preclinical data for ERAS-0015 was based on improper comparisons and risked patent and trade secret violations. Nano-X Imaging faces a class period from March 31, 2025 to April 17, 2026, with a deadline of August 11, 2026, and allegations that the company overstated efficiency gains and demand while its production was poorly aligned with demand, leading to increased expenses and restructuring charges. Microsoft's class period is May 1, 2025 to January 28, 2026, with a deadline of August 11, 2026, and the complaint claims that Copilot products suffered from brand positioning and interoperability problems, the company's AI model ranked below competitors, and it failed to convert a significant percentage of commercial Microsoft 365 users to paid Copilot subscriptions. Black Rock Coffee Bar's class period runs from September 12, 2025 to May 12, 2026, with a deadline of August 17, 2026, and the complaint alleges that new store openings cannibalized existing revenue and the company overstated how its expansion strategy avoided sales transfer. Investors who suffered losses can contact the Law Offices of Howard G. Smith to discuss their legal rights.

Kahn Swick & Foti, LLC has notified investors in Erasca, Inc. of an August 10, 2026 deadline to apply for lead plaintiff status in a pending securities class action lawsuit. The suit, filed in the United States District Court for the Southern District of California, seeks to recover losses for shareholders who purchased Erasca shares between January 14, 2025 and April 26, 2026. The complaint alleges that the company and certain executives failed to disclose that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc., exposing Erasca to patent and trade secret violation risks, and that defendants lacked a reasonable basis for their positive statements about the drug candidate. Investors who suffered losses during the class period may contact KSF Managing Partner Lewis Kahn to learn more, and they do not need to serve as lead plaintiff to share in any potential recovery.

Pomerantz LLP has filed a class action lawsuit against Erasca, Inc. concerning potential securities fraud or unlawful business practices. Investors who purchased or acquired Erasca securities during the Class Period have until August 10, 2026, to seek appointment as Lead Plaintiff. The complaint follows Erasca's April 27, 2026, disclosure of a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015, which caused Erasca's stock to fall 10.71% to $19.50 per share. After market hours that same day, Erasca reported preliminary Phase 1 data for ERAS-0015, including a patient death, and clarified that comparisons to other product candidates were based on cross-study analyses, leading to a further 48.3% drop to $9.90 per share on April 28, 2026.

The Portnoy Law Firm has announced a class action lawsuit on behalf of Erasca, Inc. investors who purchased securities between January 14, 2025 and April 26, 2026. The complaint alleges that Erasca and certain executives failed to disclose material information, including that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections. Investors have until August 10, 2026 to file a lead plaintiff motion. The firm's founding partner has recovered over $5.5 billion for aggrieved investors.

SueWallSt has notified Erasca, Inc. stockholders that a securities class action has been filed on behalf of investors who purchased ERAS stock between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca made materially false or misleading statements about its drug candidate ERAS-0015, including claims of competitive superiority over Revolution Medicines' RMC-6236, while failing to disclose that the comparisons were cross-study analyses rather than head-to-head clinical trials and that patent infringement and trade secret misappropriation risks existed. Following corrective disclosures on April 27 and 28, 2026, shares fell from $21.49 to $9.90, a decline of approximately 53.9%. The lead plaintiff deadline is August 10, 2026. The case was filed in the United States District Court for the Southern District of California.

Grabar Law Office is investigating potential fiduciary duty breaches by officers and directors of Erasca, Insulet, Photronics, and Via Transportation. The Erasca probe concerns disclosures about its pan-RAS molecular glue candidate ERAS-0015, including alleged improper comparisons to Revolution Medicines' RMC-6236 and undisclosed intellectual property risks; on April 27, 2026, the company disclosed patent infringement allegations and preliminary Phase 1 data showing a patient death, after which its share price fell substantially. The Insulet investigation relates to manufacturing defects that led to voluntary Medical Device Corrections for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods on March 12 and May 26, 2026, due to a risk of insulin under-delivery. Photronics is being investigated over statements about strong demand for high-end IC photomask products that allegedly omitted stalled customer design releases caused by foundry utilization and cost pressures. The Via Transportation probe focuses on its September 15, 2025 IPO, with allegations that offering documents failed to disclose declining Platform Annual Run-Rate Revenue per customer and regulatory hurdles in Germany. Current long-term shareholders of each company may seek corporate governance reforms and damages through shareholder derivative actions at no personal cost.

Holzer & Holzer LLC has announced upcoming deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Erasca Inc., Nano-X Imaging Ltd., and Peabody Energy Corporation. The Erasca suit, covering purchases between January 14, 2025 and April 26, 2026, alleges misleading statements about ERAS-0015, with a lead plaintiff deadline of August 10, 2026. The Nano-X Imaging suit, for purchases between March 31, 2025 and April 17, 2026, concerns claims about operational efficiency and cash burn, with a deadline of August 11, 2026. The Peabody Energy suit, for purchases between October 14, 2024 and May 4, 2026, involves allegations regarding the Centurion mine ramp-up and growth outlook, with a deadline of August 24, 2026. Investors who suffered losses are encouraged to contact the firm to discuss their legal rights.

Hagens Berman is actively investigating claims in a securities class action against Erasca, Inc. The litigation alleges that Erasca and its senior executives misled investors about the competitive advantage, safety profile, and intellectual property surrounding its lead oncology candidate, ERAS-0015, during the class period from January 14, 2025 to April 26, 2026. The complaint claims the company used flawed preclinical comparisons to assert superiority over Revolution Medicines' RMC-6236, concealed patent infringement and trade secret misappropriation risks, and downplayed safety concerns that later included a patient death. On April 27–28, 2026, disclosures of a legal challenge from Revolution Medicines and adverse clinical data triggered a sharp stock decline that wiped out over $2.8 billion in market capitalization. Investors who purchased Erasca common stock during the class period have until August 10, 2026 to seek appointment as lead plaintiff.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Via Transportation, Zillow Group, ADMA Biologics, and Erasca, with a lead plaintiff deadline of August 10, 2026. The Via Transportation suit covers a class period from September 9, 2025 to June 9, 2026 and alleges the company failed to disclose declining ARR per customer and regulatory issues hindering its German expansion. The Zillow Group suit, covering February 11, 2025 to May 7, 2026, claims the company mischaracterized its Redfin deal as a partnership rather than an acquisition, exposing it to heightened antitrust risk. ADMA Biologics is accused of undisclosed related party transactions, channel stuffing, and inadequate internal controls during the period from August 9, 2024 to March 25, 2026. The Erasca suit, covering January 14, 2025 to April 26, 2026, alleges that preclinical data for ERAS-0015 relied on improper comparisons and risked patent and trade secret violations.

Grabar Law Office is investigating potential fiduciary duty breaches by officers and directors of ADMA Biologics, Commvault Systems, Erasca, and Hub Group. For ADMA Biologics, the probe concerns allegations of inadequate internal controls, channel-stuffing, and undisclosed related-party transactions, with a March 2026 research report claiming revenue growth was overstated. The Commvault investigation focuses on allegedly misleading statements about annual recurring revenue growth guidance for fiscal year 2026. Erasca is under scrutiny for allegedly making improper comparisons between its drug candidate ERAS-0015 and Revolution Medicines' RMC-6236, and for failing to disclose related intellectual property risks, with the stock declining after April 2026 disclosures of a patient death and patent infringement allegations. Hub Group is alleged to have issued financial statements from Q1 2023 to Q3 2025 containing material misstatements due to premature revenue recognition and understated transportation costs. Long-term shareholders who purchased before specified dates and still hold shares may seek corporate reforms and damages at no cost.

Erasca has priced an upsized public offering of 31.43 million shares of its common stock at $17.50 per share, with expected gross proceeds of approximately $550 million. The offering was increased from an initially proposed target of $500 million. All shares are being sold by the company, and underwriters have a 30-day option to purchase up to an additional 4.71 million shares at the same price. The transaction is expected to close on July 15, 2026, subject to customary conditions. Erasca intends to use the net proceeds, together with existing cash and marketable securities, to fund clinical development of its pipeline candidates, program expansions, working capital, and general corporate purposes.

Rosen Law Firm reminds purchasers of Erasca common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges Erasca, along with its CEO and CFO, made false and misleading statements about its lead oncology drug candidate ERAS-0015, touting it as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. Investors who purchased Erasca common stock during the class period may be entitled to compensation through a contingency fee arrangement. To join the class action or seek lead plaintiff status, investors must move the Court by August 10, 2026.

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. securities between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca failed to disclose it was at risk of violating patent and trade secret protections, specifically that ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines and placed Erasca at risk of infringement. On April 27, 2026, Erasca disclosed it had received a letter from RevMed’s legal counsel alleging patent infringement and trade secret misappropriation, causing Erasca’s stock price to fall from $21.49 per share on April 24, 2026, to $19.15 per share on April 27, 2026. Shareholders who wish to serve as lead plaintiff must submit their papers to the court by August 10, 2026.

Erasca faces a securities class action after its stock dropped $9.25, or 48%, following disclosures that Revolution Medicines accused Erasca of patent infringement concerning its pan-RAS molecular glue ERAS-0015 and that a patient died one month after receiving the treatment. The lawsuit, filed by Hagens Berman, seeks to represent investors who purchased Erasca common stock between January 14, 2025 and April 26, 2026. The complaint alleges Erasca misled investors by improperly comparing ERAS-0015 to Revolution Medicines' RMC-6236 and by touting intellectual property protection that exposed the company to disputes. On April 27, 2026, Erasca disclosed the patent challenge and the patient death, wiping out over $2.8 billion in market capitalization the next day. The lead plaintiff deadline is August 10, 2026.

The Schall Law Firm reminds investors of a class action lawsuit against Erasca, Inc. for alleged securities fraud. The lawsuit covers investors who purchased Erasca securities between January 14, 2025 and April 26, 2026, with a lead plaintiff deadline of August 10, 2026. The complaint alleges the company made false and misleading statements regarding preclinical data on ERAS-0015, including an improper comparison to Revolution Medicines, Inc. that risked patent violations and lacked basis for optimistic projections. When the market learned the truth, investors suffered damages.

ClaimsFiler reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Erasca, Inc. if they purchased or otherwise acquired the Company’s securities between January 14, 2025 and April 26, 2026. The lawsuit, pending in the United States District Court for the Southern District of California, alleges that Erasca and certain executives failed to disclose material information, including that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections. The case is Cheng v. Erasca, Inc., No. 26-cv-03481.

Kirby McInerney LLP reminds Erasca, Inc. investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. The lawsuit, filed on behalf of investors who purchased securities between January 14, 2025 and April 26, 2026, alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate, ERAS-0015, including improper comparisons to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose patent and trade secret risks. On April 27, 2026, Erasca disclosed a letter from RevMed alleging patent infringement and trade secret misappropriation, causing shares to fall 11% from $21.49 to $19.15. A subsequent disclosure of a patient death in a Phase 1 trial and limitations on cross-study comparisons sent shares down an additional 48% to $9.90. Investors who purchased Erasca securities may contact the firm to discuss their rights.

Holzer & Holzer reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against BitGo Holdings, Erasca, and First Solar. The BitGo suit alleges misstatements about risks from falling digital asset prices, with a deadline of August 7, 2026. The Erasca case concerns alleged misrepresentations about ERAS-0015 between January 14, 2025 and April 26, 2026, and investors have until August 10, 2026 to seek lead plaintiff appointment. The First Solar action involves claims regarding the company's ability to manage U.S. tariff policy impacts between February 26, 2025 and February 24, 2026, with a deadline of August 24, 2026.

Rosen Law Firm reminds purchasers of Erasca common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges Erasca, along with its CEO and CFO, made false and misleading statements about its lead oncology drug candidate ERAS-0015, touting it as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' competing drug candidate RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. Investors who purchased Erasca common stock during the class period may be entitled to compensation through a contingency fee arrangement. To join the class action or seek lead plaintiff status, investors must move the Court by the August 10 deadline.

The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Erasca, Nano-X Imaging, Microsoft, and Black Rock Coffee Bar, with lead plaintiff deadlines ranging from August 10 to August 17, 2026. The Erasca complaint alleges that defendants misled investors about ERAS-0015's preclinical data and related patent risks. The Nano-X case claims the company overstated efficiency gains and demand while facing rising expenses and cash burn. Microsoft is accused of concealing problems with its Copilot products, including poor AI model performance and low paid subscription conversion. Black Rock Coffee Bar allegedly failed to disclose that new store openings were cannibalizing existing sales. Investors who suffered losses may contact the law firm to discuss their legal rights.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of BitGo Holdings, Erasca, Nano-X Imaging, and Microsoft, with lead plaintiff deadlines in August 2026. For BitGo, the class period runs from January 22, 2026 to May 13, 2026, with a deadline of August 7, 2026; the complaint alleges the company understated risks from declining digital asset prices. Erasca's class period is January 14, 2025 to April 26, 2026, with a deadline of August 10, 2026, and the suit claims preclinical data for ERAS-0015 was based on improper comparisons and risked patent violations. Nano-X Imaging faces a class period from March 31, 2025 to April 17, 2026, with a deadline of August 11, 2026, over allegations it overstated efficiency gains and demand while masking rising expenses and cash burn. Microsoft's class period is May 1, 2025 to January 28, 2026, also with an August 11, 2026 deadline, and the complaint alleges the company failed to disclose significant problems with its Copilot products, poor AI model benchmarks, and the need for billions in extra capital expenditures that diverted resources from Azure, leading to low paid subscription conversion and market share losses.

Kahn Swick & Foti, LLC notifies Erasca, Inc. investors of an August 10, 2026 deadline to seek lead plaintiff appointment in a securities class action lawsuit. The lawsuit, filed in the United States District Court for the Southern District of California, covers investors who purchased Erasca shares between January 14, 2025 and April 26, 2026. The complaint alleges that Erasca and certain executives failed to disclose that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc., exposing the company to patent and trade secret violation risks, and that defendants lacked a reasonable basis for positive statements about ERAS-0015. Investors who suffered losses may contact Lewis Kahn at 1-877-515-1850 or lewis.kahn@ksfcounsel.com for more information.

Pomerantz LLP has filed a class action lawsuit against Erasca, Inc. concerning potential securities fraud or unlawful business practices. Investors who purchased or acquired Erasca securities during the Class Period have until August 10, 2026, to seek appointment as Lead Plaintiff. The lawsuit follows disclosures on April 27, 2026, that Revolution Medicines alleged patent infringement and trade secret misappropriation related to Erasca's ERAS-0015, causing Erasca's stock to fall 10.71% to $19.50 per share. After market hours that same day, Erasca reported preliminary Phase 1 data for ERAS-0015, including a patient death classified as a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5, and acknowledged that comparisons with other product candidates were based on cross-study analyses and not head-to-head trials, leading to a further 48.3% drop to $9.90 per share on April 28, 2026.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Erasca, Inc. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Erasca securities between January 14, 2025 and April 26, 2026. The complaint claims defendants made false or misleading statements and failed to disclose that ERAS-0015's preclinical data relied on improper comparisons to Revolution Medicines, Inc., exposing Erasca to patent and trade secret violation risks, and that defendants lacked a reasonable basis for their positive statements about ERAS-0015. Investors have until August 10, 2026 to seek lead plaintiff appointment. The firm represents investors on a contingency fee basis.

Levi & Korsinsky reminds shareholders of Erasca, Inc. that August 10, 2026 is the deadline to seek lead plaintiff appointment in a securities class action. The lawsuit names CEO Jonathan Lim and CFO David Chacko as individual defendants, alleging they made misleading statements about the ERAS-0015 drug candidate. The class period runs from January 14, 2025 through April 26, 2026, during which the company's stock fell 53.9% after disclosures of patent infringement allegations and a patient death in trials. The complaint claims the officers signed false Sarbanes-Oxley certifications and were motivated to inflate the stock price to facilitate a $258.8 million offering that closed in January 2026.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Erasca, Inc. in the United States District Court for the Southern District of California on behalf of purchasers of Erasca common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges that the company made false and misleading statements and failed to disclose that ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines, Inc., placing Erasca at risk of violating patent and trade secret protections. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015, causing the stock to drop 48 percent from $19.15 to $9.90 per share. Investors have until August 10, 2026 to seek lead plaintiff appointment.

Moore Law PLLC is investigating potential claims against officers and directors of Erasca, Inc. over allegations that the company made false or misleading statements about its drug candidate ERAS-0015. The investigation concerns claims that positive statements about ERAS-0015 lacked a reasonable basis, as preclinical data was allegedly based on improper comparisons to Revolution Medicines and placed Erasca at risk of patent and trade secret violations. On April 27, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, and demanding an end to deceptive comparative statements. Following the news, Erasca’s stock fell from $21.49 per share on April 24 to $19.15 per share on April 27. Shareholders may be able to seek monetary damages and corporate governance reforms on a contingency fee basis.

Berger Montague has filed a securities fraud class action lawsuit against Erasca, Inc. on behalf of investors who purchased or acquired Erasca common stock between January 14, 2025 and April 26, 2026. The suit alleges that the company misrepresented its lead drug candidate ERAS-0015 as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' RMC-6236. On April 27, 2026, Erasca disclosed accusations of patent infringement and trade secret misappropriation from Revolution Medicines, and reported preliminary clinical data including a patient death while admitting its comparisons relied on cross-study analyses rather than head-to-head trials. Erasca's stock fell more than 45% on the news. Investors have until August 10, 2026 to seek appointment as lead plaintiff.